GLP-1-based medicines, such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), have become some of the most widely discussed therapies in medicine. For medical device investors they raise a secondary question: which companion devices that support, enhance or enable this therapy have a durable business, and which are borrowing the attention? “GLP-1 adjacent” positioning deserves the same diligence as any other device thesis, and sometimes more.
This article sets out the main companion device categories, the diligence questions for each, and the red flags that separate a defensible company from a borrowed narrative.
The GLP-1 Device Landscape
GLP-1 therapy touches several device categories across the patient journey:
1. Drug Delivery Systems
Injectable GLP-1 medicines are generally supplied in drug-maker pens, so delivery innovation often depends on a pharmaceutical partner. Categories include autoinjectors and other self-injection systems, wearable on-body injectors, and longer-acting approaches such as implantable depots.
Diligence focus: the regulatory pathway (a drug-device combination product developed with the drug's sponsor, or a device that must show compatibility with an approved drug?), manufacturing complexity and scale-up risk, the patent landscape around the drug and its delivery, and whether payers would pay for the delivery system separately from the drug.
2. Continuous Glucose Monitors
Glucose monitoring matters for patients with diabetes on GLP-1 therapy, and the market has widened beyond insulin users: in March 2024, FDA cleared Dexcom's Stelo, the first over-the-counter continuous glucose monitor, for adults who do not use insulin. The category is led by large, well-funded incumbents with established reimbursement relationships.
The catch: a new entrant needs a clear advantage, such as better accuracy, lower cost or integration with delivery or coaching systems.
Red flag: “a CGM optimized for GLP-1 patients” without a differentiated clinical value proposition. CGM performance is judged on accuracy (mean absolute relative difference, MARD), wear duration and data integration, not on a population label.
3. Metabolic and Body Composition Monitoring
Some companies pitch wearables or patches that estimate metabolic markers, such as resting metabolic rate or energy expenditure, as companions to GLP-1 therapy. The diligence question is how the data would change a clinical decision. Products that collect data without a decision attached tend to be wellness products, and FDA's January 2026 general wellness guidance draws the line between wellness and medical claims; see our article on that guidance.
Body composition is a more concrete clinical question. Weight loss on GLP-1 therapy includes lean mass as well as fat, so tools that measure body composition accurately and help guide interventions such as resistance training may have clinical value, if the evidence supports them.
4. Behavioral Coaching and App-Based Monitoring
Digital programs that combine medication tracking, nutrition and exercise coaching and clinician communication are a crowded, well-funded field. Depending on their claims, these products may be non-device wellness software or regulated software functions, so the regulatory position has to be read from the intended use; see our article on software misclassification.
Diligence focus: integration with drug makers, pharmacy benefit managers or health plans, exclusive data relationships, and evidence of outcomes. A standalone app without those may struggle to hold its price.
5. Complications and Aftercare
Some clinical needs grow alongside GLP-1 use. Wegovy's prescribing information, for example, warns of acute gallbladder disease: in weight-reduction trials, cholelithiasis was reported in 1.6% of patients on Wegovy injection and 0.7% of patients on placebo. Substantial weight loss can also bring patients to body contouring and related procedures. Devices in these areas are conventional surgical or aesthetic technology whose patient population may grow with GLP-1 use, and they should be diligenced on their own clinical merits rather than on the GLP-1 narrative.
The GLP-1 Device Diligence Framework
Not all “GLP-1 adjacent” positioning is equal. Four questions help separate defensible companies from borrowed narratives:
Question 1: Does the Device Solve a Real Clinical Problem?
Not a hypothetical or a nice-to-have, but a clinical issue with measurable outcomes. Examples:
- A delivery system that reduces injection burden or improves adherence, measured as adherence rates
- A body composition tool that helps clinicians identify patients losing significant muscle, measured against functional outcomes
- A surgical device that addresses a complication seen in patients on GLP-1 therapy
Red flag: “Our device provides better monitoring of GLP-1 efficacy” without defining what “better” means clinically.
Question 2: Is It Defensible Against Drug Makers and Incumbents?
GLP-1 medicines are sold by large, well-capitalized drug makers that can bundle digital tools, delivery devices and services with their products. A device that a drug maker could easily replicate or bundle is exposed. Defensibility has to come from patents, exclusive partnerships or clinical data the drug maker does not have.
Question 3: What Is the Addressable Market in the Indicated Population?
A common pitch error runs: “The GLP-1 market is huge; if we capture 1%, that is a billion-dollar business.” The addressable market is the subset of patients for whom the device is indicated and likely to be used and paid for, not a share of drug sales. An autoinjector's market, for example, depends on how many patients struggle with the existing pen, how many of those would switch, and what the device is paid.
Question 4: Who Pays?
Coverage for GLP-1 medicines, especially for weight management, varies by payer and has been changing. Will payers cover the device separately from the drug, or treat it as part of the drug's cost? Companies with payer agreements or health economic data showing device-driven savings stand on firmer ground than companies assuming coverage will follow; see our reimbursement red flags.
GLP-1 Device Red Flags
(1) “GLP-1 adjacent” positioning with no defensible differentiation. (2) Market estimates derived from a percentage of drug sales rather than the indicated patient population. (3) A reimbursement strategy that depends on GLP-1 coverage expanding. (4) No clinical data supporting the device in the population it targets. (5) An underestimated regulatory pathway, such as assuming a 510(k) when the device's features may require a De Novo request. (6) No partnership strategy with drug makers, pharmacy benefit managers or health plans where the business model needs one.
The Bottom Line
GLP-1 therapy is creating real device questions, but “GLP-1 adjacent” is a positioning statement, not a business model. Diligence should look for clinical differentiation, defensible IP or partnerships, a market estimate grounded in the indicated population rather than drug sales, and a credible answer to who pays.
References
- FDA. WEGOVY (semaglutide) prescribing information. accessdata.fda.gov
- Dexcom. "Stelo by Dexcom First Glucose Biosensor to be Cleared by FDA as Over-the-Counter." March 5, 2024. investors.dexcom.com
- FDA. "General Wellness: Policy for Low Risk Devices." Final guidance, January 2026. fda.gov
Need a Custom Analysis?
Vantage full reports assemble the public record on a company, cite factual claims to their sources, and are reviewed by Arvind Ravinutala, MD, and Aswini Ravinutala, BME. Start with a free 20-minute call.